Video Library

Explaining Treatment Regimens to Patients with HR+/HER2–Metastatic Breast Cancer

Dr Thomas Bachelot is careful to set reasonable expectations for his patients with HR+/HER2–metastatic breast cancer regarding how long their treatment will last and how it will impact them.

James F. Donohue, MD
Video Categories: Breast Cancer and ESMO

HR+/HER2- Metastatic Breast Cancer: Common Presenting Symptoms

Hope Rugo, MD, discusses common presenting symptoms of HR+/HER2- metastatic breast cancer, citing bone metastasis as the most prevalent.

James F. Donohue, MD
Video Categories: Breast Cancer and ESMO

New Effective Targets

Sunil Verma, MD, MSEd, FRCPC discusses new classes of therapies for HR+ Breast Cancer.

James F. Donohue, MD
Video Categories: Breast Cancer and ESMO

The Variability of HR+ Breast Cancer

Sunil Verma, MD, MSEd, FRCPC discusses treatment options for this type of cancer.

James F. Donohue, MD
Video Categories: Breast Cancer and ESMO

Patient Preferences

Sunil Verma, MD, MSEd, FRCPC takes up the topic of communicating with patients about what they want for their care.

James F. Donohue, MD
Video Categories: Breast Cancer and ESMO

Clinical Management for Relapsing Patients

Sunil Verma, MD, MSEd, FRCPC discusses all the patient factors when managing patients who relapse.

James F. Donohue, MD
Video Categories: Breast Cancer and ESMO

Impact of the FALCON Study

Dr Sunil Verma comments on the results of the FALCON study and how to use the data in a practical fashion to help treat patients.

James F. Donohue, MD
Video Categories: ESMO

Immunotherapy’s Role in Treating Hormone Receptor–Positive Diseases

Dr Thomas Bachelot discusses the potential for incorporating immunotherapy into the treatment of patients with hormone receptor–positive diseases but notes that the current data are weak, and further studies are needed to get a better sense of the viability of this treatment option.

James F. Donohue, MD
Video Categories: Breast Cancer and ESMO

Exploring the Uses of Fulvestrant

Dr Sibylle Loibl explains how fulvestrant (with or without palbociclib) fits in the treatment paradigm for patients with HR+/ HER2-negative metastatic breast cancer.

James F. Donohue, MD
Video Categories: Breast Cancer and ESMO

Common Issues in Treating Patients with HR+/ HER2-Negative Metastatic Breast Cancer

Dr Hope Rugo discusses some of the choices and challenges she’s faced with in treating patients with HR+/ HER2-negative metastatic breast cancer with the goal of helping patients live as long as possible and with the best quality of life.

James F. Donohue, MD
Video Categories: Breast Cancer and ESMO

Sign me up!